Pharma Journalist

2nd Flow Cytometry Congress
2020-10-08 - 2020-10-09 | London, UK
As a vital tool for providing quantifiable data on cell characteristics, flow cytometry is an integral part of diagnostics and the assessment of therapeutic efficacy. Talks will also explore the application of flow cytometry in disease monitoring and diagnosis, and approaches to implementation in the clinic.

The meeting will focus on:

Advances in flow cell and sheath fluid design.
The development of new fluorophores.
Next-generation detection systems, and
An applications session exploring the analysis of cell surface antigens, reviewing cell health, cell sorting techniques and
The role of flow cytometry in drug development.

With dedicated space in the schedule to network, this conference is the ideal forum to share knowledge and build partnerships. This meeting will allow you to keep up to date with the cutting edge of research and the opportunity to further business partnerships with those in your field.
Delegates will also have access to the co-located Liquid Biopsies Congress and qPCR and Digital PCR Congress.
Visit the event page to download the full agenda.

7th QPCR & Digital PCR Congress
2020-10-08 - 2020-10-09 | London, UK
qPCR & Digital PCR are the most essential techniques used for quantification of nucleic acid molecules in molecular biology and diagnostics.
Where qPCR is considered as a powerful technique that can provide precise and quantitative data reflecting the biology of the tested experimental parameters, the excellent precision of dPCR supports its application for the detection of rare point mutations and mutations induced by gene editing in a background of wild-type sequences.

At this congress our expert speaker panel will address these challenges in the form of case studies and interactive sessions. The agenda will focus on the challenges which need to be addressed to successful move forward into clinical studies:

Accuracy
Reproducibility
Assay optimization
Multiplexing
Standardization
Translating methods into applications

With dedicated space in the schedule to network, this conference is the ideal forum to share knowledge and build partnerships. This meeting will allow you to keep up to date with the cutting edge of research and the opportunity to further business partnerships with those in your field.
Delegates will also have access to the co-located Flow Cytometry Congress and Liquid Biopsies Congress.
Visit the event page to download the full agenda.

2nd Liquid Biopsies Congress
2020-10-08 - 2020-10-09 | London, UK
This conference offers experts working in the biopharmaceutical industry as well as academia the opportunity to examine the latest developments in the field with dedicated congress presentations, panel discussions and roundtables.

The agenda will explore :

Novel methods, research techniques, advances and discoveries in the field.
Research applications utilizing technologies such as qPCR, Digital PCR and NGS.
The detection and analysis of on circulating biomarkers such as cell-free DNA, (cfDNA), circulation tumor cells (CTCs), and extracellular vesicles (EVs).
The growing field of single cell analysis and he use of different fluids for non-invasive testing.

With dedicated space in the schedule to network, this conference is the ideal forum to share knowledge and build partnerships. This meeting will allow you to keep up to date with the cutting edge of research and the opportunity to further business partnerships with those in your field.
Delegates will also have access to the co-located Flow Cytometry Congress and qPCR & Digital PCR Congress.
Visit the event page to download the full agenda.

Animal Health Investment USA
2020-10-12 - 2020-10-13 | Venue tbc, Boston, MA, United States
Animal Health Investment USA is a premier investment forum showcasing the most exciting partner opportunities in animal health and connecting those businesses together with financial investors and strategic corporate partners.

Once again, our forum in Boston will be split into two tracks, a human biotech and animal health partnering track and an investor track. The first will be looking specifically at maximizing the therapeutic and commercial potential of human technologies and serving unmet medical needs in veterinary health, the second will be focused on driving investor engagement and showcasing the industry’s most exciting emerging companies.
We will include keynote presentations and host C-level panel discussions that address the trends and market dynamics of the animal health industry, across all species. A key element of the investment forum is the full use of a our 1-on-1 meeting scheduler, available to all attendees.
To know more about Animal Health Investment USA please click here.

3rd Targeted Protein Degradation Summit
2020-10-13 - 2020-10-15 | Digital Event – EDT
Off the back of the newly released first-in-human data utilizing PROTACs, it is more than ever evident that the field of targeted protein degradation is redefining the therapeutic landscape across the whole of the pharmaceutical industry. Despite the recent success, significant challenges are continuing to hold back the progress of the discovery and development of safe and effective protein degraders.
For the 3rd time, the TPD Summit is providing you with the leading platform that showcases the latest developments and advancements in the field, bringing together the leading biopharmaceutical and academic organizations in an intimate networking environment to focus on successfully degrading intracellular & extracellular targets, improving rational design and accelerating the translation of next generation proteasomal- & autophagy- mediated protein degraders into clinical trials.
Here is a sneak peak of just some of our 60+ world-class speaker faculty:

Jay Bradner, President, Novartis Institutes for Biomedical Research
Craig Crews, John C. Malone Professor of MCDB, Chemistry & Pharmacology, Yale University
Alessio Ciulli, Professor of Chemical & Structural Biology, University of Dundee
Matt Disney, Professor of Chemistry & Neuroscience, Scripps Research
Ian Churcher, Chief Scientific Officer, Amphista Therapeutics
John Houston, President & Chief Executive Officer, Arvinas
Ray Deshaies, Senior Vice President of Global Research, Amgen
Nello Mainolfi, Founder, President & Chief Executive Officer, Kymera Therapeutics
Stewart Fisher, Chief Scientific Officer, C4 Therapeutics
Scott Edmondson, Director & Head of Boston Oncology Chemistry, AstraZeneca
Yu Shen, Director of Cancer Biology, AbbVie
Richard Glynne, Chief Scientific Officer, Lycia Therapeutics
Ingrid Wertz, Principal Scientist & Project Team Lead, Genentech

Don’t miss the most comprehensive, industry-focused meeting in the field specifically dedicated to the discovery and development of targeted protein degradation strategies to advance your pipelines towards success!

8th Plant Genomics & Gene Editing Congress: USA
2020-10-19 - 2020-10-20 | Raleigh-Durham, USA
The Congress will explore novel strategies and developments in plant genomics and gene editing through a series of case studies and an examination of the latest scientific research. Leaders from academia and industry will consider key developments in gene editing technologies such as CRISPR/Cas9 and TALEN and discuss its application in improving disease resistance, stress tolerance and crop yield.

Discover how research institutions and agri-biotech are using gene-editing technologies to advance their research.
Learn how to apply successful bioinformatic strategies to overcome plant phenotyping challenges.
Explore the impact of gene editing regulation.
Building on existing partnerships and creating new collaborations across industry & academia

With dedicated space in the schedule to network, this conference is the ideal forum to share knowledge and build partnerships.
Visit the event page to download the full agenda.

5th Partnerships in Biocontrol & Biostimulants Congress: USA
2020-10-19 - 2020-10-20 | Raleigh-Durham, USA
Case studies across the two days will examine developments in biopesticides and biostimulants and the application of new research in increasing crop yield, improving soil health & nutrient uptake, and efficient water use. Experts from industry and academia will also discuss pest management strategies and provide regulatory updates in the field.

Discover how research institutions and agri-biotech are developing the next generation of bacterial biostimulants.
Learn how to apply successful bioinformatic strategies to advance your research.
Explore the updated understanding of biopesticides and biostimulants regulation.
Hear about insights into the role of plant and soil microbiomes.
Build on existing partnerships and create new collaborations across industry & academia.

With dedicated space in the schedule to network, this conference is the ideal forum to share knowledge and build partnerships.
Visit the event page to download the full agenda.

Microbiome for Agriculture Congress: USA
2020-10-19 - 2020-10-20 | Raleigh-Durham, USA
The meeting will examine the symbiotic relationships between microbes and plants through case studies in plant and soil microbiomes. Academic and industry leaders will discuss new research into the rhizosphere, phyllosphere and endosphere and the application of plant and soil microbiome research in improving disease resistance, nutrient acquisition and crop yield, and tolerance to multiple stressors including nematodes, insects and drought.
With dedicated space in the schedule to network, this conference is the ideal forum to share knowledge and build partnerships.
Visit the event page to download the full agenda.

5th Microbiome Movement – Drug Development Summit
2020-10-19 - 2020-10-21 | Digital Event – EDT
The 5th Microbiome Movement – Drug Development Summit (October 19-21, Digital Event – EDT) continues to be the industry-leading forum to help forward thinking researchers from the pharmaceutical, biotech and academic community pursue the causal role of the human microbiome in disease, to create a new generation of targeted treatments that demonstrate consistent clinical outcomes and predictable MoAs.

With over 60 speakers taking part, the four focus areas for 2020 include:

Pre-Clinical Development & Mechanisms of Microbiome-based Therapeutics
Learn how industry and academic pioneers are developing novel microbiome platforms to identify new targets and therapeutics across a range of microbiome-targeting modalities and disease phenotypes
Clinical Development, Manufacturing & Commercialization of Live Biotherapeutics
As the industry prepares for pivotal clinical readouts this summer, this year’s discussion will give you the knowledge and insight required to navigate through the specific translational, clinical and manufacturing challenges for live biotherapeutics
Microbiome-based Biomarkers, Diagnostics & Patient Stratification
Mine the human microbiome to discover new biomarkers of disease and help predict response, understand drug metabolism and develop non-invasive diagnostic tools
Applications in Oncology
Gain a comprehensive insight into the most exciting disease target in microbiome research today with case-studies and discussion from leading cancer researchers, oncology-specific clinicians and the pharmaceutical industry

If you are, or would like to be, a player in the microbiome arena, this is the conference you should attend to not only hear the latest pre-clinical and clinical development from organizations developing microbiome-based therapeutics, biomarkers and diagnostics, but also to make long-lasting connections that will accelerate your microbiome developments forward, and help translate this promising science into a reality for patients.

Outsourcing in Clinical Trials Nordics 2020
2020-10-20 - 2020-10-21 | Virtual Event
After the challenges of 2020 with the Covid-19 pandemic, this is the unmissable event that the pharmaceutical,
biotechnology, and medical device communities need to come together and discuss strategies for operational success in clinical trials. With all the latest content, and a big focus on the latest regulations and technology, the conference will offer an unparalleled opportunity to hear in-depth talks from the likes of the Danish Medicines Agency, LEO Pharma, and TÜV SÜD, as well as C-level and senior experts from the Nordic region.

To know more about Outsourcing in Clinical Trials Nordics 2020 please click here.

Pre-Filled Syringes East Coast 2020
2020-10-26 - 2020-10-27 | Sheraton Boston Hotel, 39 Dalton Street, Boston, MA, 02199, United States
SMi are proud to announce the 7th annual conference:
Pre-Filled Syringes East Coast 2020
26-27 October 2020
Boston, USA
Sheraton Boston Hotel
http://www.pfsamericas.com/pjwl
Innovations in parenteral device and product development

SMi Group are proud to announce the 7th Pre-Filled Syringes East Coast conference returning to Boston, USA on 26th-27th October 2020.
The global pre-filled syringes market was valued at $4.9 billion in 2018 and with the rapid growth of the industry, is expected to exceed $9.7 billion by 2025. With that in mind, for its 7th year running- the 2020 event will aim to focus on new trends on digital technology advancements, human studies and innovative design and delivery systems within the prefilled syringe industry.
Themes for 2020:
Pre-Filled Syringes East Coast 2020 will be exploring themes of Container Closure Interaction and Formulation; On-body Injectors; Digital connectivity in the parenteral space; A regulatory outlook with industry and recognised body experts; Patient centricity and device development; Developments in device technology; Parenteral gene therapy and New for 2020: PFS Interactive Workshop Day.
This comprehensive overview will help attendees understand the changing global market and the challenges faced within the industry.
This two-day agenda offers you peer-to-peer networking with Global Product Managers, Senior PFS Engineers, Device Testing Managers, Heads of Late-Stage PFS Development and many more..
Key Reasons to Attend:

EXPLORE the latest case studies parenteral drug delivery
GAIN insights into the use of pre-filled syringes for gene therapy
NETWORK with leading industry experts, key opinion leaders and regulatory body representatives
ENGAGE in the key challenges and topics of the field in the interactive post-conference workshop day

Who should attend:

Drug-delivery developers
Medical Device Engineers
Primary Packaging material designers
Secondary packagers
Smart device developers
Training device developers
Device-safety solution providers
Drug developers

To register or for more information visit: www.pfsamericas.com/pjwl
SOCIAL MEDIA HANDLES
Twitter: @SMiPharm #Smipfsusa
LinkedIn: follow our company page – search ‘SMi Pharma’

Smithers’ Extractables and Leachables USA 2020
2020-10-26 - 2020-10-28 | Virtual Event
Smithers’ 9th annual Extractables and Leachables USA conference is returning. This is a unique event in the extractables and leachables industry, bringing together top companies from the entire supply chain and making it easy to network with peers, leading to new, beneficial connections. The event is a must for the extractables and leachables industry, wherein players need to stay on top of market changes, fluctuating regulations, medical device strategies, and safety standards for consumer safety and product success. Smithers’ E&L 2020 gathers industry experts to discuss these topics, and more. The program consists of two days of industry-leading presentations by over 20 expert speakers, supplemented by valuable networking breaks, an included networking lunch, and a networking reception at the end of day one.
Companies who have attended in the past include B Braun, The FDA, Toxikon, Intertek, Abbott, Nelson Laboratories, Boston Scientific, Vimta, Jordi Labs, VR Analytical, Teknor Apex, and many more.
Visit the event website for more information: https://www.eandl-conference.com/usa.
Contact Producer Ashli Speed, ASpeed@Smithers.com, with questions about the program.
For companies interested in increasing their brand visibility in front of a target market, contact Shannon Siegferth, SSiegferth@Smithers.com, about sponsorship opportunities.
To get the latest updates, follow the event on twitter @SmithersELEvent, join the LinkedIn group Extractables and Leachables Forum, or join the mailing list: https://www.eandl-conference.com/usa/register-interest.

TIGIT Therapies Digital Summit
2020-10-26 - 2020-10-27 | Online
Priming the immune system against solid tumors by leveraging immune checkpoint blockade has proven to be an effective tool in multiple malignancies.
Following the success of PD1/PDL1 checkpoint inhibitors a new wave of ICI now enters the clinic, amongst which TIGIT has shown exciting preliminary results and sparked great excitement in this nascent field. With 27 ongoing clinical trials investigating TIGIT in front- and second-line indications, a great deal of momentum has built in this competitive space.

However, core challenges must still be addressed by the community, such as:

Investigating the TIGIT pathway, ligands, and modes of action
Optimizing biomarker strategy to identify optimal patient populations and indications
Rationalizing combination strategy to leverage the TIGIT mechanise for maximum therapeutic benefit

The TIGIT Therapies Digital Summit will gather the greatest minds in TIGIT research in a dedicated, two day meeting. Gain access to 1:1 time with leaders in TIGIT research and take away tangible learnings for your future research.
In such a fast-paced industry, this is a unique opportunity to provide an overview of the ‘knowns and unknowns’ in the field and draw a path for best practice in the safe development of TIGIT therapies with maximum clinical impact.
Working with leaders in the industry we have developed a meeting that brings together the best and brightest minds within the development of TIGIT therapies to bring you the opportunity to share invaluable insights, leverage the collective experiences of years of expertise and network and collaborate with the movers and shakers; all with the ultimate aim of accelerating the clinical to commercial development of TIGIT therapies.
At a time when we are more isolated than ever, this event will break down barriers and provide the opportunity for frank and open discussion to ensure the continued progress and development of TIGIT therapies.
Head to the TIGIT Therapies Digital Summit website to access your complimentary event guide and find out more!

4th Annual Gene Therapy for Rare Disorders Europe | Running Digitally for 2020
2020-10-26 - 2020-10-28 | Virtual Event
Realise the Commercial Potential of Gene Therapies
The 4th Annual Gene Therapy for Rare Disorders Europe is dedicated to overcoming
manufacturing, clinical, and commercialisation challenges drug developers face when delivering
gene therapies to market.
With new European gene therapy approvals rapidly approaching and investment at an all-time high, the digital meeting will leverage the experience from the first to market pioneers, as well as unveiling the strategies the next generation of drug developers are employing to improve efficacy, safety and commercial viability.

Across three days, we will virtually unite 250+ leading experts from innovative biotechs, large pharmaceutical companies, academia, and key service providers. Understand the nuances of the European regulatory landscape, engage with European payers and ensure your manufacturing and logistical approaches are set for the commercial primetime to come.
Wherever you’re based, if you’re looking to develop and launch gene therapy products in Europe, this is your comprehensive guide to define your commercial path forward
To learn more about Gene Therapy for Rare Disorders Europe please click here: https://ter.li/k19u77

TIGIT Therapies Digital Consortium
2020-10-27 | Online
Priming the immune system against solid tumors by leveraging immune checkpoint blockade has proven to be an effective tool in multiple malignancies.
Following the success of PD1/PDL1 checkpoint inhibitors a new wave of ICI now enters the clinic, amongst which TIGIT has shown exciting preliminary results and sparked great excitement in this nascent field. With 27 ongoing clinical trials investigating TIGIT in front- and second-line indications, a great deal of momentum has built in this competitive space.

However, core challenges must still be addressed by the community, such as:

Investigating the TIGIT pathway, ligands, and modes of action
Optimizing biomarker strategy to identify optimal patient populations and indications
Rationalizing combination strategy to leverage the TIGIT mechanise for maximum therapeutic benefit

The TIGIT Therapies Digital Consortium will gather the greatest minds in TIGIT research in a series of monthly, themed seminars. Gain access to 1:1 time with leaders in TIGIT research and take away tangible learnings with monthly executive summaries and exclusive content after the event.
In such a fast-paced industry, this is a unique opportunity to provide an overview of the ‘knowns and unknowns’ in the field and draw a path for best practice in the safe development of TIGIT therapies with maximum clinical impact.
Working with leaders in the industry we have developed a series of working groups that bring together the best and brightest minds within the development of TIGIT therapies to bring you the opportunity to share invaluable insights, leverage the collective experiences of years of expertise and network and collaborate with the movers and shakers; all with the ultimate aim of accelerating the clinical to commercial development of TIGIT therapies.
At a time when we are more isolated than ever, these working groups will break down barriers and provide the opportunity for frank and open discussion to ensure the continued progress and development of TIGIT therapies.
Head to the TIGIT Therapies Digital Consortium website to access your complimentary event guide and find out more!

Macrophage-directed Therapies Summit 2020
2020-10-27 - 2020-10-29 | Virtual Event
Harnessing the Potential of Macrophage Therapies Using Small Molecule, Antibody & Cell Therapy based Approaches for Oncology and Beyond
With the explosive excitement and clinical proof of concepts utilizing CD47 approaches, macrophage-directed therapies have started to witness interest and investment in novel macrophage targets outside of CD47.

The 2nd Macrophage-directed Therapies Summit is focused on optimizing the potential of macrophage therapies, through direct utilization of cells or small molecule approaches to target and stimulate macrophage cells in vivo for oncological indications and beyond.
Bringing together the leading experts, we will explore the clinical development of CD47 checkpoint blockades, combination strategies, macrophage repolarization approaches and engineered macrophages.
Join the trailblazers of macrophage therapeutic development, from the likes of Carisma Therapeutics, Faron Pharmaceuticals, and Verseau Therapeutic, as we come together to advance the fundamental understanding of macrophage biology, avoiding on-target toxicities and the emerging field of macrophage cellular immunotherapy.

Pharmaceutical Microbiology East Coast
2020-10-28 - 2020-10-29 | Virtual Event
SMi’s 3rd Annual Pharmaceutical Microbiology East Coast
Conference: 28 – 29 October 2020
Location: Virtual Event
Website: www.microbiologyeastcoast.com/PJWL
SPONSORED BY: Associates of Cape Cod, bioMérieux, Bioscience International, C.T.L. MAT, LONZA
CHAIRED BY: Lynne Ensor,VP Technical, Parexel
Exploring the current approaches towards improved contamination control
The pharmaceutical microbiology industry has seen many changes during the progression into the 21st century. With advances in rapid microbiological methods, revisions being made to regulations in the industry, enhanced knowledge of the human microbiome, and novel testing methods, this industry is ever expanding.
Join industry experts to discuss and analyze the latest advances and challenges within the industry. Network with industry professionals, discuss the revision of Annex 1, explore data integrity considerations for conventional and rapid microbiology methods, analyze arising issues with environmental monitoring and gain insight into an industry perspective on automated endotoxin testing and process automation.
Event Hashtag: #SMiPharmaMicroEC
HIGHLIGHTS FOR 2020:

Discuss ongoing complication of personnel derived contaminations from the FDA
Gain valuable insight towards microbiological quality considerations in non-sterile manufacturing and control of BCC from Parexel
Learn from the perspective of the US Pharmacopeia on container closure integrity evaluation
Examine an end-to-end contamination risk assessment for autologous cell therapy from Juno Therapeutics
Explore a back to back Genentech session covering technical considerations for microbial QC of raw materials used in biotechnology and the past, current and future state of Mycoplasma testing

The Use of Recombinant Chromogenic Assays as Alternate Methods for the Bacterial Endotoxins Test (BET)
Workshop Leader:
Veronika Wills, Manager, Technical Services, Associates of Cape Cod
View the full agenda: www.microbiologyeastcoast.com/PJWL
WHO SHOULD ATTEND
Senior Microbiologist, Lead Scientist, Laboratory Manager, QA Specialist, Drug Substance External Manufacturer, QC Scientists, Heads of Quality, Business Development Manager, Pharmaceutical Microbiology Consultant, Higher Pharmacopoeia Scientist, Analytical Standards Specialist
To know more about Pharmaceutical Microbiology East Coast please click here.

Dry AMD Therapeutic Development Summit
2020-10-28 - 2020-10-29 | Virtual Event
Finding new therapeutics to counter the progression of Dry AMD and prevent the geographical atrophy has never been more important. The aging population creates an ever-growing clinical need for next-generation therapeutics.
This action-packed two-day digital agenda holds 22 Presentations from industry and academic leaders, a virtual poster session and 5+ hours of networking, you can join the only platform discussing issues present in the development of Dry AMD therapeutics.

Join this critical global forum which will be uniting industry specialists from pharma, biotechs, academia and solution providers as we target the most pressing issues important to bringing the next generation of Dry AMD drugs to market.
Companies speaking include: Genentech, 4D Molecular Therapeutics, Alkeus Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, University of California, San Francisco, Regenerative Patch Technologies, Novartis, Stealth BioTherapeutics Inc
Find out more here > https://ter.li/mc1pmz

Patient-to-Patient Supply for Cell Immunotherapies Summit
2020-10-29 - 2020-10-30 | Digital Event
Achieving Standardization & Operational Excellence in Vein-to-Vein Supply
As an increasing number of candidates enter the clinic and promise to be a mainstay in the future of cancer treatment, cell therapies pose unique supply chain challenges.

At the inaugural Patient-to-Patient Supply for Cell Immunotherapies Summit, this community will share their expertise and propose best practice for seamless vein-to-vein delivery at the clinical and commercial scale.
From time and temperature sensitivity, to patient-facing service and integrated platforms, a seamless vein-to-vein supply chain is central in maintaining cell immunotherapy safety and efficacy at scale and maximizing the patient experience.
Join the strategic experts from GSK, bluebird bio, Adaptimmune, Celgene, BMS and more, to discuss best practice for patient-facing supply chains and build integrated platforms for chain of identity and end-user access.

Digital 5th Neoantigen Based Therapies Summit
2020-11-03 - 2020-11-05 | Online | Digital Event
With all eyes on the explosive neoantigen field watching to see how it can revolutionize cancer immunotherapies and rival the current T cell therapies, it is clear that critical questions still remain to be addressed to ensure full therapeutic success.

Taking place from the comfort of your own home this year, the 5th Neoantigen Based Therapies Summit remains the only industry focused meeting dedicated to the full end-to-end development and commercialization of neoantigen-based cancer immunotherapies.
View the full event guide for more details on this content packed 3-day virtual event.
We’ll be addressing the most pressing challenges in the field, including:

Identifying both personalized and shared Neoantigens to supercharge development of next generation immunotherapy with University of Miami and Netherlands Cancer Institute
Improving prediction accuracy by exploring different neoantigen sources with Ervaxx, Precision Biologics and Broad Institute
How to maximize immunogenicity to drive clinical development & success with Gritstone Oncology, Genocea and Treos Bio
Reducing complex process and release times by navigating through complex manufacturing challenges with Achilles Therapeutics, Vaximm and ISA Therapeutics

Download the official brochure to see what sessions will help you to advance your cancer immunotherapy pipeline.
Join us online to gain the practical insights you need to improve the immune response and commercial viability of your neoantigen based cancer immunotherapy.

8th Microbiome R&D & Business Collaboration Forum: USA
2020-11-05 - 2020-11-06 | San Diego, USA
This forum has a long-standing reputation for bringing together leading academic and industry microbiome researchers. Presentations will feature the latest research into the human microbiome as well as effective business and commercialization strategies for new products.

Topics covered on the agenda include:

IBD, Colitis, and Metabolic Diseases
Gut-brain axis
Women’s health
Skin & Cosmeceuticals
Personalized nutrition
Business Collaboration – Regulations & Investment
Probiotics & Prebiotics
Roundtable discussions

With dedicated space in the schedule to network, this conference is the ideal forum to share knowledge and build partnerships.
Visit the event page to download the full agenda.

2nd Skin Microbiome & Cosmeceuticals Congress: USA
2020-11-05 - 2020-11-06 | San Diego, USA
This congress will explore the burgeoning field of skin microbiome research, with case studies focused on topics such atopic dermatitis, psoriasis, acne, and allergy, and the microbiome-based products being developed to fight these diseases. The conference also provided insight into the future of microbiome-based cosmetics, with numerous presentations given on trial design, commercial strategy, and consumer awareness and expectations.
With dedicated space in the schedule to network, this conference is the ideal forum to share knowledge and build partnerships.
Visit the event page to download the full agenda.

5th Probiotics & Prebiotics Congress: USA
2020-11-05 - 2020-11-06 | San Diego, USA
This Congress will include numerous presentations on probiotics discovery and product development, as well as prebiotics, diet and nutrition. Alongside several case studies on digestive health, metabolic diseases, ageing and allergy, the conference highlighted the importance of the early life microbiome, the milk microbiome, and the use of probiotics to modulate the infant gut.
With dedicated space in the schedule to network, this conference is the ideal forum to share knowledge and build partnerships.
Visit the event page to download the full agenda.

3rd Annual Lab Asset & Facility Management in Pharma 2020
2020-11-10 - 2020-11-12 | Virtual Event
The 3rd Lab Asset & Facility Management in Pharma will return to Boston this Winter as your ONLY industry led meeting focusing on R&D asset and FM, enabling you to regain control of your assets, optimize your space and benchmark best practices to stay ahead of the curve.

Through strategic planning and rolling out digital tracking, Lab Asset, Operations and FM Directors are beginning to regain control of their inventory, asset value and optimize facility footprint to:

Reduce unnecessary downtime and ensure reliable business operations
Strengthen relationships and drive innovative partnership models with OEMs
Maximize asset lifecycle and value – and make informed financial decisions during purchasing, renewing, reselling and auctioning
Optimize lab and working space, implementing the ethos of shared economy within the R&D scientific community
Enhance capital efficiency to re-invest in drug development programs
Anticipate expansion from a lab and equipment perspective

Digital Neuropsychiatric Drug Development Summit
2020-11-10 - 2020-11-12 | Virtual Event
The 3rd Annual Neuropsychiatric Drug Development Summit will return in November 2020 as an interactive, virtual meeting. This definitive industry meeting is focused on helping you develop the next generation of more clinically effective therapeutics.

With an emphasis on depressive disorders, schizophrenia, addiction and PTSD, this timely meeting provides a much-needed platform for industry and academic thought leaders to:

Dive into novel therapeutic approaches for PTSD with Aptinyx, Bionomics, Tonix & MAPS
Uncover the emergence of the next generation of anti-psychotics with Karuna Therapeutics, NeuroRx & Intra-cellular Therapeutics
Explore industry approaches for innovative trial design and new methods to modelling the placebo response with Novartis, Otsuka & Yale University
Hear how pioneering biotechs are spearheading drug development for substance use disorders with Opiant Pharmaceuticals & the NIDA
Learn how to advance neurophysiology and cognition translational biomarkers and be part of the drive towards precision medicine with Takeda & UT Southwestern

Uniting 60+ drug developers from all corners of the world, Neuropsychiatric Drug Development is your opportunity to discuss in depth how to push forward the frontiers of neuropsychiatric drug development to develop the next generation of more clinically effective therapeutics.
To know more about Digital Neuropsychiatric Drug Development Summit please click here.

TIDES Europe: Oligonucleotide & Peptide Therapeutics 2020
2020-11-10 - 2020-11-13 | 100% Virtual
Europe’s #1 forum for oligonucleotide, peptide, CRISPR and mRNA therapeutic leaders to discuss scientific strategies and accelerate products to market, while also creating new successful partnerships. This year’s virtual agenda features 5 scientific tracks covering in-depth development strategies, trends and technologies across the entire oligonucleotide and peptide spectrum; as well as a partnering track that will keep you ahead of your competition, and work towards collaborations.

2nd Annual Biomarkers for Rare Non-Oncological Disorders
2020-11-10 | Digital Event
The Digital 2nd Annual Biomarkers for Rare Non-Oncological Diseases Summit will unite biopharma, diagnostic and healthcare teams to advance the application of precision medicine in rare diseases beyond oncology.
This event is completely free for Drug Developers, Researchers and Academics. To register your complimentary pass, simply follow this link: www.nononcologyraredisease-summit.com/take-part/register/
Tackling critical challenges from early research through to late-stage market access, this meeting is the must-attend summit for industry-led insights in delivering novel treatments for patients in need.
How Will it Help You Deliver Predictive Markers & Effective Drug-Dx Products?
Drawing on a multitude of disease areas spanning neurology, cardiology, metabolic, renal, inflammatory and more, the meeting combines a range of perspectives and experiences for unparalleled learning opportunities.
With 2 days of in-depth case studies, interactive panel discussions, dedicated Q+A time and valuable networking opportunities, you can walk away with improved end-to-end strategies from early biomarker validation to effective clinical trials and enabling successful regulatory, payer and commercial discussions.
Take a look at the full event guide to see all case studies, pre-conference workshop details and the full expert speaker faculty!

Microbiome Connect: Skin 2020
2020-11-10 - 2020-11-11 | Virtual Event
2019 proved to be a pivotal year for the skin microbiome, as personal care giants Unilever launched their Dove range of ‘microbiome-friendly’ skincare products. Clearly, the biggest players in beauty and personal care have recognised the potential commercial value of skin microbiome-based consumer product claims and formulations.

Moving forward into 2021, the market will continue to see more and more products launched with microbiome claims backed through next-generation sequencing techniques. Including ingestible beauty products that influence the gut-skin axis, to truly personalised skincare solutions and mass market formulations – there’s a huge commercial opportunity to commercialise skin microbiome research into consumer care products.
So, what’s different at Microbiome Connect: Skin EU Virtual?
Six new topics to explore:

The skin-gut axis and the development of ingestible beauty products.
Personalisation of skin-microbiome products and formulation considerations.
Defining skin-microbiome industry terminology and developing scientifically backed claims that resonate with consumers.
Next generation sequencing techniques and their application in claims development.
New data demonstrating the role of the microbiome in common skin conditions including acne, eczema and dandruff.
The vaginal and oral microbiomes and the mass market product development opportunities to treat gingivitis/periodontitis and sexually transmitted infections.

All tickets to tune into this event are 2FOR1 – simply quote this when booking online!

2nd Digital Exosome Based Therapeutic Development Summit
2020-11-11 - 2020-11-12 | Digital Event
The exosome therapeutics field is booming with anticipation as preparations are underway for the first few clinical trials and money pours in through partnerships and pipeline acquisitions. However, more is needed to be done to uncover more scientific knowledge, fine-tune manufacturing methods and prepare trials to meet regulatory expectations.
Considering this, the 2nd Digital Exosome Based Therapeutic Development Summit (November 11-12, 2020) will unite pharma, biotech, academic and technology providers to advance exosome therapeutics into a clinical and commercial reality.

This is your only industry-focused meeting dedicated specifically to evidence-based and regulated exosome-based therapeutics. Bringing together industry leaders and newcomers on the field, it’s two days not to be missed.
With 20+ speakers and 2 days of unrivalled in-depth content, join your peers to discuss:

End-to-end insights on drug development from discovery to scalable manufacturing of GMP-grade exosomes, clinical preparation, commercial strategy and more with Evox Therapeutics, Aruna Bio, Codiak Biosciences and ReNeuron
Innovations in exosome-based therapeutics, such as their applications in COVID-19 vaccines with Capricor Therapeutics
Understanding the underlying mechanisms of exosome interactions to inform target identification and development decisions with Scripps Research and University Hospital Essen
Preparing for clinical trials with key lessons learned from the best in the business such as Aegle Therapeutics
Over 4+ hours scheduled virtual networking time to connect with the community all from the comfort of your own home or office!

If you are exploring the therapeutic applications of exosomes in an evidence-based approach, this is the place for you.
Spanning 2 days, this digital program is tailor-made to showcase the field’s most exciting breakthroughs to inform your discovery, manufacturing, commercial and regulatory strategies. Join this interactive forum this November to drive GMP-grade manufacturing methods, consistent exosome production, improved isolation and purification, effective clinical and regulatory preparations, beneficial industry partnerships and more.
To know more about 2nd Digital Exosome Based Therapeutic Development Summit please click here.

Microbiome Connect: Human 2020
2020-11-12 | Virtual Event
Microbiome Connect: Human EU has been postponed this year due to the impacts of COVID-19. However, at Microbiome Connect, we’re committed to continue providing a platform for scientific presentations and networking opportunities for the microbiome community before we return to face-to-face again in 2021.

This November, we’ll be running a free-to-attend virtual symposium highlighting some of the latest scientific activity. Tune in for free on 12th November, 2020.
Agenda:
9.30 – 10:00 AM | Iron and the gut microbiome: an opportunity for LBPs functional during active gut inflammation
Jenny Bailey – CEO – Ferryx
10.15 – 10:40 AM | Gut-Brain axis mechanism of action and Clinical results on Hafnia alvei HA4597, a new probiotic strain for the regulation of appetite and weight management
Gregory Lambert – CEO – Targedys
10:55 – 11:20 AM | Rationally Designed Probiotic
Dr. Olaf Larsen – Senior Manager Science – Yakult Nederland B.V.
Register for free online.
